Table 4.
Predicted versus actual treatment category based on midazolam clearance (Qmet) cut-points
| Predicted category and midazolam clearance cut-point | Inhibition | No modulation | Induction |
|---|---|---|---|
| (4.82–16.4 L/h) | (16.4–41.8 L/h) | (41.8–88.9 L/h) | |
| Actual treatment—original dataset | |||
| Inhibition [N (%)] | 59 (93.7) | 4 (6.35) | 0 (0) |
| No modulation [N (%)] | 2 (1.35) | 146 (98.6) | 0 (0) |
| Induction [N (%)] | 0 (0) | 0 (0) | 12 (100) |
| Actual treatment—external validation set | |||
| Inhibition [N (%)] | 72 (83.7) | 14 (16.3) | 0 (0) |
| No modulation [N (%)] | 1 (5.00) | 19 (95.0) | 0 (0) |
| Induction [N (%)] | 0 (0) | 15 (62.5) | 9 (37.5) |
| Actual treatment—external validation set, no weak induction | |||
| Inhibition [N (%)] | 72 (83.7) | 14 (16.3) | 0 (0) |
| No modulation [N (%)] | 1 (5.00) | 19 (95.0) | 0 (0) |
| Induction [N (%)] | 0 (0) | 4 (33.3) | 8 (66.7) |
| Actual treatment—both sets | |||
| Inhibition [N (%)] | 131 (87.9) | 18 (12.1) | 0 (0) |
| No modulation [N (%)] | 3 (1.79) | 165 (98.2) | 0 (0) |
| Induction [N (%)] | 0 (0) | 15 (41.7) | 21 (58.3) |
| Actual treatment—both sets, no weak induction | |||
| Inhibition [N (%)] | 131 (87.9) | 18 (12.1) | 0 (0) |
| No modulation [N (%)] | 3 (1.79) | 165 (98.2) | 0 (0) |
| Induction [N (%)] | 0 (0) | 4 (16.7) | 20 (83.3) |